Clinical Trials
6
Active:0
Completed:4
Trial Phases
2 Phases
Phase 2:1
Phase 4:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)β’ Click on a phase to view related trials
Phase 4
4 (80.0%)Phase 2
1 (20.0%)A Study Evaluating Efficacy and Safety of CRO-SBT in the Treatment of Gonorrhea
Phase 4
Completed
- Conditions
- Gonorrhea
- Interventions
- First Posted Date
- 2019-12-17
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- Xiangbei Welman Pharmaceutical Co., Ltd
- Target Recruit Count
- 113
- Registration Number
- NCT04202068
PHase IV Clinical Trial of Ceftriaxone Sodium and Sulbactam Sodium for Injection (CRO-SBT)
Phase 4
Completed
- Conditions
- Respiratory Tract InfectionsUrinary Tract Infections in Children
- Interventions
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Xiangbei Welman Pharmaceutical Co., Ltd
- Target Recruit Count
- 30
- Registration Number
- NCT04066621
Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection
Phase 4
- Conditions
- Respiratory Tract InfectionsUrinary Tract Infections
- Interventions
- Drug: xin te mie
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2013-07-12
- Lead Sponsor
- Xiangbei Welman Pharmaceutical Co., Ltd
- Target Recruit Count
- 2000
- Registration Number
- NCT01897831
Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection
Phase 4
Completed
- Conditions
- Respiratory Tract InfectionsUrinary Tract Infections
- Interventions
- First Posted Date
- 2013-01-03
- Last Posted Date
- 2019-07-08
- Lead Sponsor
- Xiangbei Welman Pharmaceutical Co., Ltd
- Target Recruit Count
- 2000
- Registration Number
- NCT01760109
- Locations
- π¨π³
Chongqing Red Cross hospital, Chongqing, China
Study on Ceftazidime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection
Phase 2
Suspended
- Conditions
- Respiratory Tract InfectionsUrinary Tract Infections
- Interventions
- First Posted Date
- 2012-05-17
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Xiangbei Welman Pharmaceutical Co., Ltd
- Target Recruit Count
- 288
- Registration Number
- NCT01601093
- Locations
- π¨π³
the First Affiliated Hospital With Medical University, Nanjing, Jiangsu, China
- Prev
- 1
- 2
- Next
News
No news found